NASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free PTGX Stock Alerts $28.69 +0.21 (+0.74%) (As of 01:15 PM ET) Add Compare Share Share Today's Range$28.13▼$29.2550-Day Range$23.96▼$32.1552-Week Range$13.72▼$33.34Volume91,134 shsAverage Volume731,600 shsMarket Capitalization$1.67 billionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Protagonist Therapeutics alerts: Email Address Protagonist Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside27.8% Upside$36.00 Price TargetShort InterestBearish5.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.11Based on 2 Articles This WeekInsider TradingSelling Shares$1.94 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom $1.18 to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.61 out of 5 starsMedical Sector693rd out of 939 stocksPharmaceutical Preparations Industry321st out of 434 stocks 3.5 Analyst's Opinion Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.00, Protagonist Therapeutics has a forecasted upside of 27.8% from its current price of $28.18.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.87% of the outstanding shares of Protagonist Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 16.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTGX. Previous Next 2.8 News and Social Media Coverage News SentimentProtagonist Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Protagonist Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of -84% compared to the previous 30 days.MarketBeat Follows6 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,939,592.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $1.18 to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is -18.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is -18.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 4.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Protagonist Therapeutics Stock (NASDAQ:PTGX)Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Read More PTGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTGX Stock News HeadlinesMarch 27, 2024 | markets.businessinsider.comProtagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic PartnershipsMarch 18, 2024 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with TakedaMarch 28, 2024 | Huge Alerts (Ad)Trending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! March 15, 2024 | finance.yahoo.comPTGX Apr 2024 15.000 callMarch 15, 2024 | finance.yahoo.comPTGX Apr 2024 30.000 putMarch 12, 2024 | bizjournals.comThe People's Market owner snaps up former Protagonist space in heart of NoDa for barMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113March 11, 2024 | markets.businessinsider.comStrong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial OutlookMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 3, 2024 | finance.yahoo.comThis Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This YearMarch 2, 2024 | finance.yahoo.comEarnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their EstimatesMarch 1, 2024 | finance.yahoo.comProtagonist Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 29, 2024 | finance.yahoo.comWe're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash BurnFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic PartnershipsFebruary 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Gritstone Oncology (GRTS), Protagonist Therapeutics (PTGX)February 25, 2024 | seekingalpha.comProtagonist Therapeutics: Why I Remain On Sidelines Despite Obvious PromiseFebruary 21, 2024 | finance.yahoo.comNew England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia VeraFebruary 20, 2024 | finance.yahoo.comProtagonist Therapeutics Reports Granting of Inducement AwardsFebruary 17, 2024 | finance.yahoo.comPTGX Mar 2024 25.000 callFebruary 15, 2024 | finance.yahoo.comSteven Cohen Adjusts Position in Protagonist Therapeutics IncFebruary 8, 2024 | msn.comProtagonist Pictures Ups Janina Vilsmaier, Mounia Wissinger, Strengthens Sales and Marketing DivisionsFebruary 8, 2024 | msn.comProtagonist Pictures Promotes Janina Vilsmaier & Mounia Wissinger; Bolsters Sales & Marketing Teams Ahead Of EFMFebruary 7, 2024 | finance.yahoo.comNew England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis StudyFebruary 2, 2024 | markets.businessinsider.comBuy Rating on Protagonist Therapeutics: Strategic Takeda Partnership and Rusfertide’s Market PotentialFebruary 1, 2024 | msn.comProtagonist Therapeutics stock rises on Takeda license dealFebruary 1, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and Protagonist Therapeutics (PTGX)February 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics Following Strategic Takeda Collaboration and Promising Drug PipelineSee More Headlines Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PTGX CUSIPN/A CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees112Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$38.00 Low Stock Price Target$32.00 Potential Upside/Downside+23.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E Ratio24.64 P/E GrowthN/ANet Income$-78,960,000.00 Net MarginsN/A Pretax Margin-131.59% Return on Equity-27.49% Return on Assets-25.30% Debt Debt-to-Equity RatioN/A Current Ratio16.71 Quick Ratio16.71 Sales & Book Value Annual Sales$60 million Price / Sales28.24 Cash FlowN/A Price / Cash FlowN/A Book Value$5.84 per share Price / Book4.98Miscellaneous Outstanding Shares58,280,000Free Float55,361,000Market Cap$1.69 billion OptionableOptionable Beta2.05 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Dinesh V. Patel Ph.D. (Age 67)CEO, President, Secretary & Director Comp: $883.46kDr. Suneel K. Gupta Ph.D. (Age 65)Chief Development Officer Comp: $640.89kDr. Mark Smythe Ph.D. (Age 59)Founder & VP Technology Mr. Asif Ali (Age 50)Executive VP & Chief Financial Officer Mr. Mohammad Masjedizadeh Ph.D.Executive VP & Chief Technical OfficerMr. Matthew M. Gosling (Age 53)Executive VP & General Counsel Ms. Carena SpiveySenior Vice President of Human ResourcesDr. Ashok Bhandari Ph.D. (Age 60)Executive VP & Chief Drug Discovery and Preclinical Development Officer Dr. Scott Eric Plevy M.D.Executive VP & Therapeutic Head of GastroenterologyMr. Carter J. King (Age 53)Executive Vice President of Business Development More ExecutivesKey CompetitorsAgios PharmaceuticalsNASDAQ:AGIOMorphicNASDAQ:MORFDynavax TechnologiesNASDAQ:DVAXEdgewise TherapeuticsNASDAQ:EWTXTaro Pharmaceutical IndustriesNYSE:TAROView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 74,478 shares on 3/11/2024Ownership: 5.412%Dinesh V Ph D PatelSold 30,000 sharesTotal: $948,600.00 ($31.62/share)Goldman Sachs Group Inc.Bought 48,017 shares on 3/1/2024Ownership: 0.884%Asif AliSold 14,248 sharesTotal: $459,355.52 ($32.24/share)William D WaddillSold 12,975 sharesTotal: $406,636.50 ($31.34/share)View All Insider TransactionsView All Institutional Transactions PTGX Stock Analysis - Frequently Asked Questions Should I buy or sell Protagonist Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PTGX shares. View PTGX analyst ratings or view top-rated stocks. What is Protagonist Therapeutics' stock price target for 2024? 4 brokers have issued 12 month price targets for Protagonist Therapeutics' stock. Their PTGX share price targets range from $32.00 to $38.00. On average, they anticipate the company's share price to reach $36.00 in the next year. This suggests a possible upside of 27.8% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts. How have PTGX shares performed in 2024? Protagonist Therapeutics' stock was trading at $22.93 at the beginning of 2024. Since then, PTGX shares have increased by 22.9% and is now trading at $28.18. View the best growth stocks for 2024 here. When is Protagonist Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PTGX earnings forecast. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its quarterly earnings data on Tuesday, February, 27th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.05 by $0.39. The business had revenue of $60 million for the quarter, compared to analyst estimates of $60 million. What ETF holds Protagonist Therapeutics' stock? Invesco Dorsey Wright Healthcare Momentum ETF holds 129,690 shares of PTGX stock, representing 1.50% of its portfolio. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE). When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.22%), Vanguard Group Inc. (5.47%), Vanguard Group Inc. (5.41%), Point72 Asset Management L.P. (4.53%), Kynam Capital Management LP (3.48%) and Price T Rowe Associates Inc. MD (1.43%). Insiders that own company stock include Asif Ali, David Y Liu, Dinesh V Ph D Patel, Suneel Gupta and William D Waddill. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTGX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.